4CPS-170 Evaluation of zoledronic acid in the treatment of bone diseases with high risk of fractures

BACKGROUND: Zoledronic acid (ZOL) administered as a 5 mg intravenous infusion anually is indicated for the treatment of bone diseases such as Paget disease and osteoporosis with a high risk of fracture. It is strongly advised that patients treated with ZOL receive adequate calcium and vitamin D (cal...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Eur J Hosp Pharm
मुख्य लेखकों: Puivecino-Moreno, C, Alcalá-Soto, A, Vázquez-Vela, V, Jiménez-Pichardo, L, Varas-Pérez, A, Marín-Ariza, I, Gómez-de-Travecedo-Calvo, MT
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BMJ Group 2018
विषय:
Section 4: Clinical pharmacy services
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535356/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.260
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन